Automated synthesis of 68Ga/177Lu-PSMA on the Trasis miniAllinOne
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Automated synthesis of 68Ga/177Lu-PSMA on the Trasis miniAllinOne. / Sørensen, Mikkel A.; Andersen, Valdemar L.; Hendel, Helle Westergren; Vriamont, Charles; Warnier, Corentin; Masset, Julien; Huynh, Tri Hien Viet.
In: Journal of Labelled Compounds and Radiopharmaceuticals, Vol. 63, No. 8, 2020, p. 393-403.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Automated synthesis of 68Ga/177Lu-PSMA on the Trasis miniAllinOne
AU - Sørensen, Mikkel A.
AU - Andersen, Valdemar L.
AU - Hendel, Helle Westergren
AU - Vriamont, Charles
AU - Warnier, Corentin
AU - Masset, Julien
AU - Huynh, Tri Hien Viet
PY - 2020
Y1 - 2020
N2 - Prostate-specific membrane antigen (PSMA)-based radioligands for positron emission tomography (PET)/computed tomography (CT) studies represent the gold standard for detection of recurrent prostate cancer (PCa). [68Ga]PSMA-HBED-CC is a PET radiotracer suitable for detection of PCa, and its clinical use has become widespread over the last few years. In this contribution, we detail our GMP-compliant production of [68Ga]PSMA-HBED-CC using the Trasis miniAllinOne radiosynthesizer and report synthetic and clinical data for the first 100 productions of 2019. Additionally, we detail our efforts towards a GMP-compliant production of the radiotherapeutic [177Lu]PSMA-I&T using the same synthesis module. PSMA-based radioligand therapy (RLT) offers a possible future treatment in cases of metastatic castration-resistant PCa, and GMP-compliant routine production methods are therefore called for. This report highlights how PSMA-based agents for theranostic purposes can be conveniently produced at a single radiochemistry Good Manufacturing Practice (GMP) site, thereby facilitating optimized detection and treatment of PCa.
AB - Prostate-specific membrane antigen (PSMA)-based radioligands for positron emission tomography (PET)/computed tomography (CT) studies represent the gold standard for detection of recurrent prostate cancer (PCa). [68Ga]PSMA-HBED-CC is a PET radiotracer suitable for detection of PCa, and its clinical use has become widespread over the last few years. In this contribution, we detail our GMP-compliant production of [68Ga]PSMA-HBED-CC using the Trasis miniAllinOne radiosynthesizer and report synthetic and clinical data for the first 100 productions of 2019. Additionally, we detail our efforts towards a GMP-compliant production of the radiotherapeutic [177Lu]PSMA-I&T using the same synthesis module. PSMA-based radioligand therapy (RLT) offers a possible future treatment in cases of metastatic castration-resistant PCa, and GMP-compliant routine production methods are therefore called for. This report highlights how PSMA-based agents for theranostic purposes can be conveniently produced at a single radiochemistry Good Manufacturing Practice (GMP) site, thereby facilitating optimized detection and treatment of PCa.
KW - GMP
KW - PET/CT
KW - prostate cancer
KW - PSMA
KW - [Lu]PSMA-I&T
KW - [Ga]PSMA-HBED-CC
UR - http://www.scopus.com/inward/record.url?scp=85085704707&partnerID=8YFLogxK
U2 - 10.1002/jlcr.3846
DO - 10.1002/jlcr.3846
M3 - Journal article
C2 - 32374450
AN - SCOPUS:85085704707
VL - 63
SP - 393
EP - 403
JO - Journal of Labelled Compounds and Radiopharmaceuticals
JF - Journal of Labelled Compounds and Radiopharmaceuticals
SN - 0362-4803
IS - 8
ER -
ID: 260203758